Key Highlights
- Total Revenue was USD 259.94 million against an estimate of USD 245.47 million.
- Diluted EPS was USD 0.35 against an estimate of USD 0.36.
- U.S. BRIUMVI net revenue was approximately USD 233 million, up 52% year-over-year.
- Full-year U.S. BRIUMVI revenue guidance was raised to USD 915 million to USD 920 million.
TG Therapeutics (NASDAQ:TGTX) reported third quarter 2026 total revenue of USD 259.94 million, compared with USD 161.71 million in the third quarter of 2025. The revenue estimate stood at USD 245.47 million. Diluted Earnings per Share were USD 0.35, against an estimate of USD 0.36, and Net Income was USD 55.5 million.
Net product revenue was USD 240.0 million, including USD 7.4 million of product sales to the company's ex-U.S. partner, Neuraxpharm. License, milestone, Royalty and other revenue was USD 19.9 million, which included a USD 10 million sales milestone from that partner. The company's chief financial officer said total revenue was up 61% year-over-year.
BRIUMVI Sales and Profitability
U.S. BRIUMVI net revenue was approximately USD 233 million, up 52% from a year earlier. The company's chief commercial officer described the quarter as the 14th consecutive period of sequential growth for the product. U.S. BRIUMVI gross Margin was 87%, and consolidated gross margin was approximately 84%.
Operating income was USD 85.9 million, compared with USD 29.4 million in the third quarter of 2025. Research and Development and selling, general and administrative expenses, excluding stock-based compensation, were approximately USD 107 million, including about USD 10 million for subcutaneous BRIUMVI and secondary source manufacturing. The company's chief financial officer compared this with USD 150 million of total operating expenses in the second quarter. Net income in the third quarter of 2025 was USD 390.9 million and included a non-cash income tax benefit from the release of a deferred tax valuation allowance.
Guidance and Capital Allocation
The company raised its 2026 U.S. BRIUMVI net product revenue guidance from USD 890 million to USD 905 million to a new range of USD 915 million to USD 920 million. Total global revenue guidance is approximately USD 1 billion, including projected payments from the ex-U.S. partner. The chief commercial officer said the range reflects more than USD 260 million for the fourth quarter. Guidance for research and development and selling, general and administrative expenses, excluding stock-based compensation, remains at USD 450 million to USD 500 million.
The company held approximately USD 557 million in cash equivalents and Investment securities at the end of September. During the quarter it repurchased USD 100 million of common stock, or roughly 2 million shares at an average price of about USD 49. Repurchases across all programs total USD 300 million, or roughly 8.9 million shares, at an average price below USD 34.
Pipeline and Regulatory Updates
Chief Executive Officer Michael Weiss said the company is targeting potential approval around mid-2027 of a consolidated single initiation infusion for IV BRIUMVI, following the ENHANCE study meeting its primary endpoint. Top-line results from the Phase III study of subcutaneous BRIUMVI are anticipated around year-end or early 2027, and the company is targeting a potential launch in 2028.
At the ECTRIMS meeting, the company presented seven-year follow-up results from the ULTIMATE program and first clinical results for azer-cel, its allogeneic CAR T therapy, in 26 patients with progressive multiple sclerosis. The company is also running Phase II studies of BRIUMVI in generalized myasthenia gravis and treatment-resistant schizophrenia.
TG Therapeutics Q3 2026 Earnings: Key Takeaways
TG Therapeutics reported third quarter 2026 revenue of USD 259.94 million and diluted EPS of USD 0.35, with U.S. BRIUMVI net revenue of approximately USD 233 million. The company raised its full-year U.S. BRIUMVI revenue guidance to USD 915 million to USD 920 million, repurchased USD 100 million of common stock in the quarter and outlined timelines for its IV and subcutaneous BRIUMVI programs.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...